Ahead of NLSDays 2021, DNB conducted an interview with Genagon Therapeutics' CEO Moa Fransson. She explains why Genagon's research is important, what will happen in the company in 2021 and why NLSDays is an important platform.
Mpya Sci & Tech is one of our exciting new members. Here are four questions about 2021 for CEO Johan Östman.
We asked LINK Medical's CEO Ola Gudmundsen to share his thoughts on this exciting acquisition.
With an increase of 40 new members in 2020, SwedenBIO will have both an increased weight in speaking for the industry but also as a platform for your members to network with each other. What does one of our newest members, Vaccinfabriken, see as opportunities in 2021 and what are their expectations of membership? We ask CEO Jens Bäck.
Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection of innovation, capital and health. In the first part, we meet Adam Kostyal, Head of European Listings at Nasdaq, who looks at the stock market year for the sector, talks about the impact of the pandemic and shares his predictions for the future.
Encouragingly, the pipeline report shows a high degree of international connectivity among Swedish companies.
Research on viruses has lagged behind, but Sweden has several promising projects. The first results will be available within a week. - Scientists have long warned of a new major epidemic or pandemic but have not known when and what kind of virus it would be. So you could say it was expected," says Nina Lindblom, PhD in pharmacology and one of three employees of the member company Curovir.
How is SwedenBIO's member companies affected by the corona crisis and what does it mean for ongoing and planned clinical studies? We look at qPharmetra, which offers pharmacokinetic services to customers in the US and Europe.
How to create sustainable trading on the stock exchange
The life science sector is one of the strongest for listed small companies in Sweden. At the same time, the competition in the sector is fierce and it is necessary to work with the issues that affect share trading. A well-functioning share trading is important for creating growth in small and medium-sized companies.
Offer to you as an incubator company
Life for startup companies was not without challenges before the effects of the corona crisis hit, and the situation is now tough for many smaller companies. Now we want to contribute to building Sweden’s next generation of life science companies strong, for future export revenue and innovation power. Startup companies with up to four employees must be members of SwedenBIO for an annual fee of SEK 1,000.
Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection between innovation, capital and health. In the first part, we meet Adam Kostyal, European head of listing at Nasdaq, who looks at how the stock market year looked for the sector, talks about the impact of the pandemic and shares his predictions for the future.
